Tags

Type your tag names separated by a space and hit enter

Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of Δ(9) -THC in cannabis users.
J Clin Pharmacol. 2013 Jul; 53(7):680-90.JC

Abstract

Oral Δ(9) -tetrahydrocannabinol (Δ(9) -THC) has been evaluated as a medication for cannabis dependence, but repeated administration of acute oral doses up to 40 mg has not been effective at reducing drug-taking behavior. Larger doses might be necessary to affect cannabis use. The purpose of the present study was therefore to determine the physiological and behavioural effects of oral Δ(9) -THC at acute doses higher than those tested previously. The pharmacokinetic and pharmacodynamic profile of oral Δ(9) -THC, administered in ascending order in 15 mg increments across separate sessions, up to a maximum of 90 mg, was determined in seven cannabis users. Five subjects received all doses and two experienced untoward side effects at lower doses. Δ(9) -THC produced a constellation of effects consistent with previous clinical studies. Low cannabinoid concentrations were associated with significant effects on drug-sensitive measures, although progressively greater levels did not lead to proportionately larger drug effects. Considerable variability in Cmax and tmax was observed. Doses of oral Δ(9) -THC larger than those tested previously can be administered to individuals with a history of cannabis use, although given the pharmacokinetic variability of oral Δ(9) -THC and individual differences in sensitivity, individualized dose adjustment is needed to avoid side effects and maximize therapeutic response.

Authors+Show Affiliations

Department of Behavioural Science, University of Kentucky College of Medicine, Lexington, KY 40536‐0086, USA. jalile2@email.uky.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

23754596

Citation

Lile, Joshua A., et al. "Pharmacokinetic and Pharmacodynamic Profile of Supratherapeutic Oral Doses of Δ(9) -THC in Cannabis Users." Journal of Clinical Pharmacology, vol. 53, no. 7, 2013, pp. 680-90.
Lile JA, Kelly TH, Charnigo RJ, et al. Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of Δ(9) -THC in cannabis users. J Clin Pharmacol. 2013;53(7):680-90.
Lile, J. A., Kelly, T. H., Charnigo, R. J., Stinchcomb, A. L., & Hays, L. R. (2013). Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of Δ(9) -THC in cannabis users. Journal of Clinical Pharmacology, 53(7), 680-90. https://doi.org/10.1002/jcph.90
Lile JA, et al. Pharmacokinetic and Pharmacodynamic Profile of Supratherapeutic Oral Doses of Δ(9) -THC in Cannabis Users. J Clin Pharmacol. 2013;53(7):680-90. PubMed PMID: 23754596.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of Δ(9) -THC in cannabis users. AU - Lile,Joshua A, AU - Kelly,Thomas H, AU - Charnigo,Richard J, AU - Stinchcomb,Audra L, AU - Hays,Lon R, Y1 - 2013/06/10/ PY - 2013/02/05/received PY - 2013/03/31/accepted PY - 2013/6/12/entrez PY - 2013/6/12/pubmed PY - 2014/3/5/medline SP - 680 EP - 90 JF - Journal of clinical pharmacology JO - J Clin Pharmacol VL - 53 IS - 7 N2 - Oral Δ(9) -tetrahydrocannabinol (Δ(9) -THC) has been evaluated as a medication for cannabis dependence, but repeated administration of acute oral doses up to 40 mg has not been effective at reducing drug-taking behavior. Larger doses might be necessary to affect cannabis use. The purpose of the present study was therefore to determine the physiological and behavioural effects of oral Δ(9) -THC at acute doses higher than those tested previously. The pharmacokinetic and pharmacodynamic profile of oral Δ(9) -THC, administered in ascending order in 15 mg increments across separate sessions, up to a maximum of 90 mg, was determined in seven cannabis users. Five subjects received all doses and two experienced untoward side effects at lower doses. Δ(9) -THC produced a constellation of effects consistent with previous clinical studies. Low cannabinoid concentrations were associated with significant effects on drug-sensitive measures, although progressively greater levels did not lead to proportionately larger drug effects. Considerable variability in Cmax and tmax was observed. Doses of oral Δ(9) -THC larger than those tested previously can be administered to individuals with a history of cannabis use, although given the pharmacokinetic variability of oral Δ(9) -THC and individual differences in sensitivity, individualized dose adjustment is needed to avoid side effects and maximize therapeutic response. SN - 1552-4604 UR - https://www.unboundmedicine.com/medline/citation/23754596/Pharmacokinetic_and_pharmacodynamic_profile_of_supratherapeutic_oral_doses_of_Δ_9___THC_in_cannabis_users_ L2 - https://doi.org/10.1002/jcph.90 DB - PRIME DP - Unbound Medicine ER -